# A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Source: https://onco.cc/trials/nct06979596/  
OnCo record `nct06979596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Opevesostat, Dexamethasone, Fulvestrant, Exemestane, Megestrol acetate and Tamoxifen in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) is a phase 2 interventional study registered as NCT06979596 by Merck Sharp & Dohme LLC, with 250 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-11-04. Interventions recorded: Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant and Exemestane.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06979596
- Phase: 2
- Setting: A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT06979596: https://clinicaltrials.gov/study/NCT06979596

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Exemestane](https://onco.cc/drugs/exemestane/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Megestrol acetate](https://onco.cc/drugs/megestrol/), [Opevesostat](https://onco.cc/drugs/opevesostat/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06979596.json